Refine by
Antibiotic Treatment Articles & Analysis
32 news found
Fortunately, most people who get the infection get better without antibiotic treatment in 5 to 7 days, according to the agency.” Past outbreaks have taken place in healthcare centers, nursing homes, restaurants, water parks, schools, and daycare centers. ...
Their versatility extends to applications in cancer treatment and wound healing, making them a significant focus of biotechnological research. Antibiotics, natural products predominantly produced by microorganisms, hold a crucial role in combating infectious diseases. Alfa Chemistry’s portfolio includes a diverse collection of antibiotics ...
Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, unveils the addition of the reliable Daptomycin ReadyMade™ Solution to its growing portfolio of innovative products to power up spectrum and microbiology applications. Daptomycin is an essential antibiotic used in the treatment ...
The company has launched the Phage Whole-Genome Sequencing to help discover biomarkers and develop non-antibiotic treatment methods. Phages are a group of viruses that invade bacteria, some of which can cause lysis of the host bacteria and some of which can confer additional biological properties to the genetic material of the host bacteria. ...
Periprosthetic joint infections (PJIs) are typically extremely hard to treat,[i] but this new research finds that photodisinfection may be an exciting new treatment approach. The research team, lead by PD Dr. med. Yvonne Achermann is planning further clinical research on the safety and efficacy of the PJI treatment. ...
MerLion Pharmaceuticals GmbH (MerLion), a pharmaceutical company focused on the development of novel antibiotics, reported the receipt of the final meeting minutes from the U.S. Food and Drug Administration (FDA) following a successful Type C meeting with the Agency on the development of the antibiotic finafloxacin for the treatment of ...
The LIAISON MeMed BV test is the first fully automated solution, which utilizes host response-based data to enable physicians to differentiate accurately between bacterial and viral infections, supporting fast and better-informed treatment and patient management decisions. The test also drives laboratory operational efficiency through time-labor reduction by using a fully ...
ByMeMed
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic ...
A pre-planned exploratory analysis from the ECOSPOR III trial shows that approximately two-thirds of CDI recurrences occurred within the first two weeks following antibiotic treatment for CDI – the window of vulnerability – when the microbiome is further decimated and C. difficile spores, untouched by antibiotics, are free to ...
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
” Recurrent CDI causes approximately half a million infections each year in the United States, including up to 165,000 recurring infections and up to 45,000 deaths. Existing treatments include antibiotics, which can further damage the gut microbiome. ...
Among participants who did not respond to initial treatment, an optional additional treatment course was administered, resulting in overall rates of treatment success of up to 84.4%. ...
Unfortunately, many medications, such as anticancer, antibiotics, and antifungal treatments, have severe toxicities when overdosed and are ineffective when underdosed. ...
The data further highlight the clinical benefits of using the Accelerate Pheno system, with significant improvements in multiple endpoints, including a statistically significant reduction in 30-day mortality in the Accelerate Pheno arm (AXDX) versus standard of care testing arm (SOC) in a subset of patients on ineffective empirical antibiotic treatment (6.0% in ...
The EB003 CRISPR-based killing mechanism also abolished Shiga-toxin production, compared to antibiotic treatment, which can on the contrary lead to Shiga-toxin overproduction. ...
While necessary to treat initial infection, antibiotics are also a predominant risk factor for recurrence because they can disrupt the gut microbiome, leaving the current treatment paradigm for recurrent infection incomplete,” said Paul Feuerstadt, MD, FACG, AGAF, PACT Gastroenterology, Hamden, Conn., Assistant Clinical Professor of Medicine, Yale ...
MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors. ...
The post-cataract surgery lens may be able to deliver a combination corticosteroid, NSAID and antibiotic treatment from a single lens. Ophthalmologists will apply the lens after the cataract surgery and patients can wear the lens for one week or longer to deliver the medication, instead of needing to use multiple eye drops every day. ...
S. aureus is a leading cause of serious bloodstream infections worldwide, such as infectious endocarditis and sepsis, which have been recognized as difficult to treat and often require intensive and prolonged antibiotic treatment. Lars Wegner, CEO of Evaxion, said: “We are pleased to have this paper published in Scientific Reports in collaboration with the ...
As a result, middle ear infections are the #1 reason for antibiotic prescriptions and #1 reason for surgery in children. "Our goal is to decrease the usage of antibiotic therapy by 50% for the treatment of middle ear infections," said Caitlin Cameron, CEO OtoNexus Medical Technologies. ...